Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib for hydroxyurea-resistant sickle cell disease pain crises
IRCT20180603039959N6Phase 2Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in sickle cell disease (SCD), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Number of hospitalizations, Duration of hospitalizations and 1 more. Started Oct 2025; status: completed.
02
Drugs
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on IRCT20180603039959N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180603039959N6.